B细胞-话题@MedSci

#B细胞#

314篇内容 | 4723人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273260, encodeId=d93712e326088, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JCO：循环肿瘤DNA作为弥漫大B细胞淋巴瘤早期结局预测指标, objectType=article, longId=147188, objectId=34ac14e18870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ac14e18870, replyNumber=0, likeNumber=92, createdTime=2018-08-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ac14e18870, moduleTitle=JCO：循环肿瘤DNA作为弥漫大B细胞淋巴瘤早期结局预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34ac14e18870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273259, encodeId=acad12e3259b2, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效, objectType=article, longId=145755, objectId=8b22145e5508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b22145e5508, replyNumber=0, likeNumber=63, createdTime=2018-08-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b22145e5508, moduleTitle=Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b22145e5508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273258, encodeId=ef2f12e32584c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Neurology：弥漫性大B细胞淋巴瘤表现为双侧相继受累的动眼神经病变, objectType=article, longId=145217, objectId=49aa14521efb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49aa14521efb, replyNumber=0, likeNumber=80, createdTime=2018-07-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49aa14521efb, moduleTitle=Neurology：弥漫性大B细胞淋巴瘤表现为双侧相继受累的动眼神经病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49aa14521efb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273257, encodeId=4f3112e325798, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：肿瘤特异性T细胞不能根除淋巴瘤起始B细胞！, objectType=article, longId=144636, objectId=797e14463657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=797e14463657, replyNumber=0, likeNumber=56, createdTime=2018-07-19, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=797e14463657, moduleTitle=Blood：肿瘤特异性T细胞不能根除淋巴瘤起始B细胞！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=797e14463657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273256, encodeId=365412e325660, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Brit J Haematol：原发性纵隔B细胞淋巴瘤前线管理，R-CHOP vs DA-R-EPOCH, objectType=article, longId=144543, objectId=35051445433e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35051445433e, replyNumber=0, likeNumber=114, createdTime=2018-07-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35051445433e, moduleTitle=Brit J Haematol：原发性纵隔B细胞淋巴瘤前线管理，R-CHOP vs DA-R-EPOCH, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35051445433e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273255, encodeId=0c2012e325545, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet Haematol：R-GemOx一线治疗弥漫性大B细胞淋巴瘤老年患者怎么样？, objectType=article, longId=144538, objectId=cc1d14453882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc1d14453882, replyNumber=0, likeNumber=71, createdTime=2018-07-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc1d14453882, moduleTitle=Lancet Haematol：R-GemOx一线治疗弥漫性大B细胞淋巴瘤老年患者怎么样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc1d14453882)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273254, encodeId=b9ed12e3254d5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=《B细胞慢性淋巴增殖性疾病诊断与鉴别诊断中国专家共识(2018年版)》解读, objectType=article, longId=142014, objectId=8f2314201407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f2314201407, replyNumber=0, likeNumber=41, createdTime=2018-07-01, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f2314201407, moduleTitle=《B细胞慢性淋巴增殖性疾病诊断与鉴别诊断中国专家共识(2018年版)》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f2314201407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273253, encodeId=d0ae12e325397, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率, objectType=article, longId=141010, objectId=cb7914101089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7914101089, replyNumber=0, likeNumber=26, createdTime=2018-06-20, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7914101089, moduleTitle=Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb7914101089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273252, encodeId=4d8912e32528c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, objectType=article, longId=140766, objectId=ed6f140e66a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed6f140e66a3, replyNumber=0, likeNumber=61, createdTime=2018-06-15, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed6f140e66a3, moduleTitle=Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed6f140e66a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273251, encodeId=19f412e3251ee, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2018.V4）, objectType=article, longId=138795, objectId=e0e8138e95cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0e8138e95cb, replyNumber=0, likeNumber=26, createdTime=2018-05-23, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0e8138e95cb, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2018.V4）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0e8138e95cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273250, encodeId=c9fa12e3250f9, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Clin Oncol：奥秘皆在细微处：诊断治疗间期与新诊断弥漫大B细胞淋巴瘤预后相关, objectType=article, longId=137495, objectId=28c313e4959f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c313e4959f, replyNumber=0, likeNumber=85, createdTime=2018-05-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c313e4959f, moduleTitle=J Clin Oncol：奥秘皆在细微处：诊断治疗间期与新诊断弥漫大B细胞淋巴瘤预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c313e4959f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273249, encodeId=0e9f12e324964, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物, objectType=article, longId=137448, objectId=21c913e448d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21c913e448d2, replyNumber=0, likeNumber=56, createdTime=2018-05-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21c913e448d2, moduleTitle=Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21c913e448d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273248, encodeId=451d12e324823, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：代谢异质性和总肿瘤病灶糖酵解均可作为原发纵膈B细胞淋巴瘤（PMBCL）预后预测标志物, objectType=article, longId=137142, objectId=131c13e1420c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=131c13e1420c, replyNumber=0, likeNumber=63, createdTime=2018-05-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=131c13e1420c, moduleTitle=Blood：代谢异质性和总肿瘤病灶糖酵解均可作为原发纵膈B细胞淋巴瘤（PMBCL）预后预测标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=131c13e1420c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273247, encodeId=909a12e324707, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=【重磅】厉害了！FDA批准Kymriah用于复发/难治大B细胞淋巴瘤治疗, objectType=article, longId=137081, objectId=3c9113e08130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c9113e08130, replyNumber=0, likeNumber=62, createdTime=2018-05-04, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c9113e08130, moduleTitle=【重磅】厉害了！FDA批准Kymriah用于复发/难治大B细胞淋巴瘤治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c9113e08130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273246, encodeId=804012e324661, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Allergy Asthma Immunol Res：过敏性鼻炎患者中外周B细胞子类型分析, objectType=article, longId=136958, objectId=92fb136958e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92fb136958e4, replyNumber=0, likeNumber=98, createdTime=2018-05-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92fb136958e4, moduleTitle=Allergy Asthma Immunol Res：过敏性鼻炎患者中外周B细胞子类型分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92fb136958e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273245, encodeId=031e12e3245a8, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：肿瘤抑制因子——前列腺凋亡反应蛋白4（Par-4），在慢性B细胞淋巴瘤中竟是促进细胞增殖！, objectType=article, longId=136694, objectId=c84213669400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84213669400, replyNumber=0, likeNumber=52, createdTime=2018-04-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84213669400, moduleTitle=Blood：肿瘤抑制因子——前列腺凋亡反应蛋白4（Par-4），在慢性B细胞淋巴瘤中竟是促进细胞增殖！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84213669400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273244, encodeId=b6c912e324441, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究, objectType=article, longId=136587, objectId=884f13658e71, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=884f13658e71, replyNumber=0, likeNumber=80, createdTime=2018-04-28, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=884f13658e71, moduleTitle=Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=884f13658e71)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273243, encodeId=95e212e3243bf, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2018.V3）, objectType=article, longId=136397, objectId=50dc13639e81, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50dc13639e81, replyNumber=0, likeNumber=22, createdTime=2018-04-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50dc13639e81, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2018.V3）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50dc13639e81)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273242, encodeId=66d412e32428e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：里程碑式研究：弥漫性大B细胞淋巴瘤分类迈出更精准一步, objectType=article, longId=135549, objectId=cdbc1355495e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdbc1355495e, replyNumber=0, likeNumber=75, createdTime=2018-04-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdbc1355495e, moduleTitle=NEJM：里程碑式研究：弥漫性大B细胞淋巴瘤分类迈出更精准一步, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdbc1355495e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273241, encodeId=0bbb12e32413a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Semin Arthritis Rheu：B细胞消除治疗原发性抗磷脂综合征严重血小板减少的长期疗效, objectType=article, longId=135480, objectId=26901354806d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26901354806d, replyNumber=0, likeNumber=61, createdTime=2018-04-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26901354806d, moduleTitle=Semin Arthritis Rheu：B细胞消除治疗原发性抗磷脂综合征严重血小板减少的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26901354806d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JCO：循环肿瘤DNA作为弥漫大B细胞淋巴瘤早期结局预测指标

2018-08-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：来那度胺联合obinutuzumab用于复发性/难治性滤泡性B细胞淋巴瘤的安全性和疗效

2018-08-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Neurology：弥漫性大B细胞淋巴瘤表现为双侧相继受累的动眼神经病变

2018-07-27

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：肿瘤特异性T细胞不能根除淋巴瘤起始B细胞！

2018-07-19

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Brit J Haematol：原发性纵隔B细胞淋巴瘤前线管理，R-CHOP vs DA-R-EPOCH

2018-07-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet Haematol：R-GemOx一线治疗弥漫性大B细胞淋巴瘤老年患者怎么样？

2018-07-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

《B细胞慢性淋巴增殖性疾病诊断与鉴别诊断中国专家共识(2018年版)》解读

2018-07-01

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：用JAK1/2抑制剂治疗骨髓增生性肿瘤（MPN）可增加患者恶性B细胞淋巴瘤的发病率

2018-06-20

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Res：用新型蛋白质靶向降解技术克服Ibrutinib耐药的B细胞恶性肿瘤

2018-06-15

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：B细胞淋巴瘤（2018.V4）

2018-05-23

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Clin Oncol：奥秘皆在细微处：诊断治疗间期与新诊断弥漫大B细胞淋巴瘤预后相关

2018-05-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物

2018-05-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：代谢异质性和总肿瘤病灶糖酵解均可作为原发纵膈B细胞淋巴瘤（PMBCL）预后预测标志物

2018-05-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

【重磅】厉害了！FDA批准Kymriah用于复发/难治大B细胞淋巴瘤治疗

2018-05-04

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Allergy Asthma Immunol Res：过敏性鼻炎患者中外周B细胞子类型分析

2018-05-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：肿瘤抑制因子——前列腺凋亡反应蛋白4（Par-4），在慢性B细胞淋巴瘤中竟是促进细胞增殖！

2018-04-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：PI3Kδ抑制剂（INCB040093）单独或联合JAK1抑制剂（itacitinib）用于复发性/难治性B细胞淋巴瘤的安全性和疗效研究

2018-04-28

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：B细胞淋巴瘤（2018.V3）

2018-04-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：里程碑式研究：弥漫性大B细胞淋巴瘤分类迈出更精准一步

2018-04-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Semin Arthritis Rheu：B细胞消除治疗原发性抗磷脂综合征严重血小板减少的长期疗效

2018-04-18

科室
- - 订阅+
  - 更多科室
工具
服务